source
- Novartis licenses preclinical radioligand from China's BoomRay in up to $900 million dealNovartis has expanded its radiopharmaceutical pipeline by signing a licensing agreement with Chinese biotech BoomRay Therapeutics. The deal could be worth up to $900 million, including an upfront…
- Amgen’s Horizon-acquired drug dazodalibep meets primary endpoint in phase 3 Sjögren’s trialAmgen announced that its investigational fusion protein dazodalibep, acquired through Horizon Therapeutics, achieved its primary goal in a phase 3 study of patients with moderate to severe Sjögren’…